他扎罗汀酸亚砜 | 603952-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫铬烷
• 中文名称: 他扎罗汀酸亚砜
• 英文名称: Tazarotenic acid sulfoxide
• 英文别名: 6-[2-(4,4-dimethyl-1-oxo-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylic acid
• CAS: 603952-64-3
• 化学式: C₁₉H₁₇NO₃S
• 分子量: 339.415
• InChiKey: SMCJVZRFBIOWHW-UHFFFAOYSA-N

物化性质

• 熔点：
  >185oC (dec.)
• 沸点：
  594.6±50.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-[2-(3,4-二氢-4,4-二甲基-2H-1-苯并噻喃-6-基)乙炔基]-3-吡啶甲酸 在 CYP₂₆ 作用下， 生成 他扎罗汀酸亚砜
  参考文献：
  名称：

  Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases

  摘要：

  The CYP26s are responsible for metabolizing retinoic acid and play an important role in maintaining homeostatic levels of retinoic acid. Given the ability of CYP2C8 to metabolize retinoic acid, we evaluated the potential for CYP2C8 inhibitors to also inhibit CYP26. In vitro assays were used to evaluate the inhibition potencies of CYP2C8 inhibitors against CYP26A1 and CYP26B1. Using tazarotenic acid as a substrate for CYP26, IC50 values for 17 inhibitors of CYP2C8 were determined for CYP26A1 and CYP26B1, ranging from approximate to 20nM to 100M, with a positive correlation observed between IC(50)s for CYP2C8 and CYP26A1. An evaluation of IC50's versus in vivo C-max values suggests that inhibitors such as clotrimazole or fluconazole may interact with CYP26 at clinically relevant concentrations and may alter levels of retinoic acid. These findings provide insight into drug interactions resulting in elevated retinoic acid concentrations and expand upon the pharmacophore of CYP26 inhibition.

  DOI：

  10.1080/14756366.2016.1193734

文献信息

• [EN] TAZAROTENE DERIVATIVES<br/>[FR] DÉRIVÉS DE TAZAROTÈNE
  申请人：STIEFEL LABORATORIES

  公开号：WO2011009023A1

  公开（公告）日：2011-01-20

  The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

  目前所描述的主题涉及到新的他扎罗汀衍生物，它们也表现出类视黄醇活性，包括这些衍生物的制药组合物，使用这些制药组合物治疗皮肤疾病的方法，以及制造这些衍生物的过程。
• TAZAROTENE DERIVATIVES
  申请人：Ge Xue

  公开号：US20120115909A1

  公开（公告）日：2012-05-10

  The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

  目前所述的主题涉及到塔扎罗汀的新衍生物，这些衍生物也表现出类视黄醇活性，包括这些衍生物的制药组合物、使用这些制药组合物治疗皮肤疾病的方法以及制备这些衍生物的过程。
• Topical retinoid compositions
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US10716781B2

  公开（公告）日：2020-07-21

  The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.

  本申请涉及外用组合物。特别是，本申请涉及一种外用组合物，其中包含作为活性剂的维甲酸和药学上可接受的赋形剂，以及制备这种组合物的工艺。此外，本申请还涉及使用外用组合物治疗痤疮、酒渣鼻、牛皮癣等皮肤疾病的方法。
• TOPICAL RETINOID COMPOSITIONS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20180177774A1

  公开（公告）日：2018-06-28

  The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.
• US9062037B2
  申请人：——

  公开号：US9062037B2

  公开（公告）日：2015-06-23